Literature DB >> 25960216

The microRNA-217 functions as a tumor suppressor and is frequently downregulated in human osteosarcoma.

Baoyong Sun1, Mingshan Yang2, Min Li1, Fangxin Wang1.   

Abstract

OBJECTIVE: Dysregulation of miRNA is always associated with cancer development and progression. Aberrant expression of miR-217 has been found in some types of cancer. However, its expression and function in osteosarcoma remain unclear. The aim of this study was to explore the effects of miR-217 in osteosarcoma tumorigenesis and development.
METHODS: The expression level of miR-217 was quantified by real-time RT-PCR in human osteosarcoma cell lines and tissues. MTT, flow cytometric, transwell invasion and migration assays, and tumorigenicity in vivo were adopted to observe the effects of miR-217 on MG-63 cell phenotypes.
RESULTS: MiR-217 was significantly downregulated in osteosarcoma cell lines and clinical specimens. Decreased miR-217 expression was significantly associated with large tumor size, positive distant metastasis, and advanced clinical stage. Low miR-217 expression in osteosarcoma was an independent predictor of poor survival. Overexpression of miR-217 can inhibit the proliferation, invasion, migration and promoted apoptosis of MG-63 cells in vitro and in vivo.
CONCLUSIONS: These findings indicate that miR-217 may act as a tumor suppressor in osteosarcoma and would serve as a novel therapeutic agent for miRNA-based therapy.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Invasion; MiR-217; Osteosarcoma; Prognosis; Proliferation

Mesh:

Substances:

Year:  2015        PMID: 25960216     DOI: 10.1016/j.biopha.2015.02.014

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  14 in total

1.  MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression.

Authors:  Jianting Long; Caiwen Ou; Haoming Xia; Yifan Zhu; Dayue Liu
Journal:  Tumour Biol       Date:  2015-06-06

Review 2.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

3.  MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS.

Authors:  Yi Xiao; Taoran Deng; Changliang Su; Zhen Shang
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

4.  Bladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathway.

Authors:  Zhong-Ming Huang; Hai Wang; Zhi-Gang Ji
Journal:  Inflamm Res       Date:  2021-08-14       Impact factor: 4.575

5.  MicroRNA-132 inhibits cell growth and metastasis in osteosarcoma cell lines possibly by targeting Sox4.

Authors:  Yulong Liu; Ye Li; Jingchen Liu; Yuntao Wu; Qingsan Zhu
Journal:  Int J Oncol       Date:  2015-09-07       Impact factor: 5.650

6.  Absent MicroRNAs in Different Tissues of Patients with Acquired Cardiomyopathy.

Authors:  Christine S Siegismund; Maria Rohde; Uwe Kühl; Felicitas Escher; Heinz Peter Schultheiss; Dirk Lassner
Journal:  Genomics Proteomics Bioinformatics       Date:  2016-07-28       Impact factor: 7.691

7.  The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma.

Authors:  Pingping Liu; Haiyan Yang; Jing Zhang; Xiaozhong Peng; Zhaohui Lu; Weimin Tong; Jie Chen
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

8.  Identification of epigenetic interactions between miRNA and DNA methylation associated with gene expression as potential prognostic markers in bladder cancer.

Authors:  Manu Shivakumar; Younghee Lee; Lisa Bang; Tullika Garg; Kyung-Ah Sohn; Dokyoon Kim
Journal:  BMC Med Genomics       Date:  2017-05-24       Impact factor: 3.063

Review 9.  MicroRNAs for osteosarcoma in the mouse: a meta-analysis.

Authors:  Junli Chang; Min Yao; Yimian Li; Dongfeng Zhao; Shaopu Hu; Xuejun Cui; Gang Liu; Qi Shi; Yongjun Wang; Yanping Yang
Journal:  Oncotarget       Date:  2016-12-20

10.  Anti-tumor Activity of miniPEG-γ-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy.

Authors:  Anisha Gupta; Elias Quijano; Yanfeng Liu; Raman Bahal; Susan E Scanlon; Eric Song; Wei-Che Hsieh; Demetrios E Braddock; Danith H Ly; W Mark Saltzman; Peter M Glazer
Journal:  Mol Ther Nucleic Acids       Date:  2017-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.